Epidemiology of Thyroid Cancer: A Review of the National Cancer Database, 2000-2013

Olson, Evan; Wintheiser, Grant; Wolfe, Katrina M; Droessler, Jonathan; Silberstein, Peter T.

doi:10.7759/cureus.4127

Cited by 114 publications

(110 citation statements)

References 25 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…Between 1970 and 2010, the proportion of papillary thyroid cancers increased from 58.0% to 85.9%. At the same time, the number of total thyroidectomies, which are currently the recommended method of treatment, increased 2.5 times [1,2]. Almost 75% of thyroidectomies performed just for diagnostic purposes are benign [3,4].…”

Section: Introductionmentioning

confidence: 99%

Analysis of Let-7 Family miRNA in Plasma as Potential Predictive Biomarkers of Diagnosis for Papillary Thyroid Cancer

et al. 2020

View full text Add to dashboard Cite

The most common histological type of thyroid cancer is papillary thyroid carcinoma (PTC). Radical resection of the thyroid gland is currently the recommended method of treatment. Almost 75% of thyroidectomies performed just for diagnostic purposes are benign. Thus, the confirmation of innovative and more precise noninvasive biomarkers holds promise for the detection of PTC, which may decrease the number of unnecessary thyroid lobectomies. In this work, using the droplet digital PCR (ddPCR) method, we have analyzed the level of five miRNAs (let-7a, let-7c, let-7d, let-7f, and let-7i) in the plasma of patients with PTC and compared them with those of a healthy control group to investigate whether miRNAs also have value in the management of PTC. Levels of four miRNAs, namely let-7a, let-7c, let-7d, and let-7f, were significantly higher in PTC patients than healthy controls. Thus, the analysis of circulating let-7 can be a useful tool and support the currently used methods for PTC diagnosis. However, our observation requires further research on a larger patient group.

show abstract

Section: Introductionmentioning

confidence: 99%

Analysis of Let-7 Family miRNA in Plasma as Potential Predictive Biomarkers of Diagnosis for Papillary Thyroid Cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Papillary thyroid cancer (PTC) is the most common thyroid neoplasm constituting between 58% and 85.9% of thyroid malignancies [1]. This prevalence is similar to our local setting, where PTC accounts for 85% of all thyroid cancers [2].…”

Section: Introductionmentioning

confidence: 85%

Metastatic Papillary Thyroid Carcinoma Arising in a Neglected Goiter: A Case Report

Nasir

Peter

Azraai

et al. 2020

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: Periodical clinical surveillance for early thyroid cancer detection among patients with diffuse goiter is a common scenario managed in the primary care setting. However, clinical palpation alone is neither sensitive nor specific in detecting the presence of nodules within a goiter. Hence, further investigation with ultrasound is key to effective surveillance for early detection of thyroid cancer. CASE REPORT: We present a case of a stable diffuse goiter in a 51-year-old woman diagnosed 30 years ago who refused further imaging investigation. Based solely on clinical palpation, the presence of nodules within the goiter was missed. This resulted in transformation into papillary thyroid carcinoma with lung metastases. She presented with progressive hoarseness of voice and cough for 3 months. An ultrasound of the thyroid gland revealed a large heterogeneous nodule in the left lower pole with coarse calcification and internal vascularity. Further imaging with contrast-enhanced computed tomography of the neck and thorax revealed an enhancing nodule in the left thyroid lobe which extends inferiorly to the left retroclavicular region which compresses the trachea causing narrowing of its lumen at T1 and T2 vertebral levels. There were multiple lung nodules in both lungs suggestive of metastases. CONCLUSION: A total thyroidectomy followed by radioactive iodine thyroid ablation therapy was performed. The histopathological examination revealed the surgical specimen to be papillary thyroid carcinoma.

show abstract

“…• There are four main types of thyroid cancer: the more common papillary and follicular forms (differentiated thyroid cancers), and the rare medullary and anaplastic forms (poorly differentiated thyroid cancers) [58][59][60].…”

Section: Panel 2 Exploring the Risks Of Thyroid C-cell Tumors With Gmentioning

confidence: 99%

“…• Medullary thyroid carcinoma (MTC) is a rare tumor originating from thyroid C cells [59][60][61] and accounts for approximately 2% of thyroid cancer cases in the US [58].…”

Section: Panel 2 Exploring the Risks Of Thyroid C-cell Tumors With Gmentioning

confidence: 99%

Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?

Brunton

Mosenzon

Wright

2020

Postgraduate Medicine

View full text Add to dashboard Cite

Oral semaglutide is the first US Food and Drug Administration-approved oral glucagon-like peptide-1 receptor agonist (GLP-1RA) for the treatment of type 2 diabetes (T2D). Prior articles within this supplement reviewed the PIONEER trial program, which demonstrated that oral semaglutide reduced glycated hemoglobin and body weight when given to patients with uncontrolled T2D on various background therapies, and had a safety profile consistent with subcutaneous GLP-1RAs. This article provides guidance on integrating oral semaglutide into clinical practice in primary care. Patient populations with T2D who may gain benefit from oral semaglutide include those with inadequate glycemic control taking one or more oral glucose-lowering medication (e.g. after metformin), patients for whom weight loss would be beneficial, patients at risk of hypoglycemia, those who would historically have been considered for treatment with asubcutaneous GLP-1RA, and those receiving basal insulin who require treatment intensification. Like other GLP-1RAs, oral semaglutide is contraindicated in those with personal/family history of medullary thyroid carcinoma, and in those with multiple endocrine neoplasia syndrome type 2, as noted in aboxed warning in the prescribing information. Oral semaglutide has not been studied in those with ahistory of pancreatitis, is not recommended in patients with suspected/ confirmed pancreatitis, and is not indicated in type 1 diabetes. When initiating oral semaglutide, gradual dose escalation is recommended to minimize the risk of gastrointestinal adverse events. As food and excess liquid reduce oral semaglutide absorption, patients should swallow the tablet with up to 4 fl oz/120 mL of water on an empty stomach upon waking, and should wait at least 30 minutes before eating, drinking, or taking other oral medications. Those managing patients should be aware of the potential impact of these dosing conditions on concomitant medications. When counseling patients, it is important to discuss these administration instructions, realistic therapeutic expectations, and strategies for mitigation of gastrointestinal events. Oral semaglutide provides a new option for add-on to initial T2D therapy (or later in the treatment paradigm), with the potential to enable more patients to benefit from the improvements in glycemic control, reductions in body weight, and low risk of hypoglycemia afforded by GLP-1RAs.

show abstract

Epidemiology of Thyroid Cancer: A Review of the National Cancer Database, 2000-2013

Cited by 114 publications

References 25 publications

Analysis of Let-7 Family miRNA in Plasma as Potential Predictive Biomarkers of Diagnosis for Papillary Thyroid Cancer

Analysis of Let-7 Family miRNA in Plasma as Potential Predictive Biomarkers of Diagnosis for Papillary Thyroid Cancer

Metastatic Papillary Thyroid Carcinoma Arising in a Neglected Goiter: A Case Report

Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?

Contact Info

Product

Resources

About